The addition of Novartis' Pluvicto to standard of care reduced the risk of radiographic progression or death by 28% in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. (Sedat ...
Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto to include hormone-sensitive prostate cancer (HSPC). The new results come from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results